IRONWOOD PHARMACEUTICALS, INC.
BOSTON, MA

Skin rash is a frequently reported adverse event in patients taking allopurinol. In some instances, a skin rash may be followed by more severe hypersensitivity reactions associated with exfoliation, fever, lymphadenopathy, arthralgia, and/or eosinophilia including Stevens-Johnson syndrome and toxic epidermal necrolysis. Associated vasculitis and tissue response may be manifested in various ways including hepatitis, renal impairment, seizures, and on rare occasions, death. Hypersensitivity reactions to allopurinol may be increased in patients with decreased renal function who are receiving thiazide diuretics and DUZALLO concurrently. DUZALLO should be discontinued immediately at the first appearance of skin rash or other signs that may indicate an allergic reaction, and additional medical care should be provided as needed Ironwood has always taken the long view: we hope to grow substantial value and, one step at a time, earn the right to build an enduring pharmaceutical company that helps people lead better lives. So we named ourselves after the ironwood tree, which can live for thousands of years in the harshest desert, creating a shaded microclimate in which life thrives. We also like that the word "ironwood" is both hard and soft. Iron like science, is undeniable and strong. Wood, like artistry and humanity, is flexible, adaptive and versatile. The two words together represent our passion for the art and science of making medicines. At Ironwood, being a shareholder is about more than holding our shares, it’s about being an owner of our business. That means we want you to understand the opportunities and risks we face, and what drives our decisions. Ownership is a responsibility we take seriously, because we are all owners, too. Learn more about our THE ART AND SCIENCE OF MAKING MEDICINES Ironwood Pharmaceuticals